Prediabetes: A must to recognise disease state

International Journal of Clinical Practice

Volumn 62, Issue 4, 2008, Pages 642-648

  Eldin, W Shehab ^a   Emara, M ^a   Shoker, A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; CANDESARTAN HEXETIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; METFORMIN; NATEGLINIDE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; TETRAHYDROLIPSTATIN; VALSARTAN;

CLINICAL TRIAL; HAZARD; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; BARIATRIC SURGERY; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; PREVALENCE; RISK FACTORS; TERMINOLOGY AS TOPIC; WEIGHT LOSS;

EID: 40449088311     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01705.x     Document Type: Review

References (47)

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979 28 : 1039 57.
2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 20 : 1183 97.
3. Kuzuya T, Nakagawa S, Satoh J et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002 55 : 65 85.
4. Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003 27 (Suppl 2 S1 152.
5. American Diabetes Association (ADA). Clinical practice recommendations. Diabetes Care 2007 30 (Suppl 1 S42 7.
6. Lopez-Alvarenga JC, Garcia-Hidalgo L, Landa-Anell MV, Santos-Gomez R, Gonzalez-Barranco J, Comuzzie A. Influence of skin color on the diagnostic utility of clinical acanthosis nigricans to predict insulin resistance in obese patients. Arch Med Res 2006 37 : 744 8.
7. Lubin MB, Lin HJ, Vadheim CM, Rotter JI. Genetics of common diseases of adulthood. Implications for prenatal counseling and diagnosis. Clin Perinatol 1990 17 : 889 910.
8. Ishida K, Mizuno A, Murakami T, Shima K. Obesity is necessary but not sufficient for the development of diabetes mellitus. Metabolism 1996 45 : 1288 95.
9. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993 16 : 642 52.
10. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998 21 : 518 24.
11. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998 47 : 699 713.
12. Harris MI. Gestational diabetes may represent discovery of preexisting glucose intolerance. Diabetes Care 1988 11 : 402 11.
13. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991 325 : 147 52.
14. Abstracts of the 18th Congress of the International Diabetes Federation. Paris, France, 24-29 August 2003. Diabetologia 2003 46 (Suppl. 2 A1 471.
15. Kohler C, Temelkova-Kurktschiev T, Schaper F, Fucker K, Hanefeld M. Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes. Dtsch Med Wochenschr 1999 124 : 1057 61.
16. Jermendy G, Hidvegi T, Hetyesi K, Biro L. Fasting or post-challenge blood glucose values for detection of glucose intolerance in screening for metabolic syndrome? Orv Hetil 2002 143 : 2247 52.
17. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001 24 : 447 53.
18. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998 317 : 1309 12.
19. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ 2006 174 : 801 9.
20. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991 34 : 891 8.
21. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997 20 : 537 44.
22. Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003 26 : 3230 6.
23. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
24. Williamson DA, Stewart TM. Behavior and lifestyle: approaches to treatment of obesity. J La State Med Soc 2005 1 : S50 5.
25. Carey VJ, Walters EE, Colditz GA et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997 145 : 614 9.
26. Sjostrom CD, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res 1997 5 : 519 30.
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 359 : 2072 7.
28. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 2004 47 : 575 80.
29. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002 51 : 2796 803.
30. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 : 517 22.
31. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
32. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004 64 : 2537 65.
33. Fournier A, Pruna A, Esper NE et al. Captopril Prevention Project - what shall we do about captopril and the risk of stroke? Nephrol Dial Transplant 2000 15 : 2 5.
34. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 1004 10.
35. Degl'Innocenti A, Elmfeldt D, Hansson L et al. Cognitive function and health-related quality of life in elderly patients with hypertension - baseline data from the Study On Cognition and Prognosis in the Elderly (SCOPE). Blood Press 2002 11 : 157 65.
36. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004 363 : 2049 51.
37. McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005 240 : 143 56.
38. Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006 166 : 2191 201.
39. Heymsfield SB, Segal KR, Hauptman J et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000 160 : 1321 6.
40. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 61.
41. Pinkney J, Kerrigan D. Current status of bariatric surgery in the treatment of type 2 diabetes. Obes Rev 2004 5 : 69 78.
42. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995 222 : 339 50.
43. Tsur A, Harman-Bohem I, Buchs AE, Raz I, Wainstein J. The guidelines for the diagnosis prevention and treatment of type 2 diabetes mellitus - 2005. Harefuah 2006 145 : 583 6.
44. Paterson KR. Population screening for diabetes mellitus. Professional Advisory Committee of the British Diabetic Association. Diabet Med 1993 10 : 777 81.
45. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003 157 : 1092 100.
46. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999 22 : 233 40.
47. Diabetes prevention program research group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007 24 : 137 44.